Biosimilars: FDA’s Four-Tiered Assessment Draws Industry Scrutiny
This article was originally published in PharmAsia News
PhRMA asks FDA to remove the categorization of a product as not similar, similar, highly similar, or similar with fingerprint-like similarity.
You may also be interested in...
Clinical pharmacology data could help biosimilar sponsors pursue a more global development plan.
The agency’s first three draft guidances on biosimilar product development describe how to characterize biosimilar and reference products and extrapolate data on one condition of use to another. FDA says interchangeability is difficult to determine now and will require a switching study.
Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.